AZN - AstraZeneca PLC

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Cellectis stock jumps on execution of $140M additional investment by AstraZeneca
• AstraZeneca says Phase 3 lung cancer trial for new Imfinzi regimen failed
• Eli Lilly expected to add $4.1B U.S. sales from new weight loss drug
• AstraZeneca succeeds in Phase 3 trial for liver cancer drug combo
• AstraZeneca lifts forecast after strong Q3, signs $2B deal for obesity drug
• AstraZeneca reports mixed Q3 earnings; raises FY23 outlook
• Xencor falls after royalty sale to Canada’s OMERS
• AstraZeneca Q3 2023 Earnings Preview
• AbbVie, GSK, Teva cited as FTC tackles improper Orange Book patents
• Earnings week ahead: Disney, AMC, Plug Power, Lucid, Realty Income and more
• AstraZeneca to invest $245M in Cellectis to strengthen gene therapy portfolio
• The European healthcare sector is expected to produce higher yields.
• Pharma, PBMs spar over rising drug costs amid public scrutiny
• FDA accepts AstraZeneca's sBLA for self-administration of flu vaccine
• AstraZeneca chief Soriot refutes reports of exit
• LumiraDx announces tie-up with AstraZeneca and Everton
• AstraZeneca drops after Phase 3 data for lung cancer therapy
• AstraZeneca's Tagrisso gets FDA priority review in lung cancer subtype
• Catalyst watch: Tesla earnings, Jerome Powell speech, UAW drama and Baidu event
• FDA experts recommend changes to flu vaccines